Matthew E Korenberg Insider Trading $LGND LIGAND PHARMACEUTICALS INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Matthew E Korenberg.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Matthew E Korenberg. Matthew E Korenberg is EVP,Finance & Strategy and CFO in LIGAND PHARMACEUTICALS INC ($LGND) and VP, Finance and CFO in LIGAND PHARMACEUTICALS INC ($LGND) and Director in Qualigen Therapeutics, Inc. ($RTTR).
Matthew E Korenberg in LIGAND PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Matthew E Korenberg: EVP,Finance & Strategy and CFO, VP, Finance and CFO
Holdings: 41,752 shares
Current Value: $4,502,536
Latest Transaction: Feb 05 2021
$LGND Market Capitalization: $2.24B
$LGND Previous Close: $107.84
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Matthew E Korenberg in LIGAND PHARMACEUTICALS INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 177.50 | 11,591 | 2,057,403 | 11,591 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 10,819 | 0 | 41,752 | 30.9 K to 41.8 K (+34.98 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 156.01 | 1,440 | 224,654 | 30,933 | 32.4 K to 30.9 K (-4.45 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 4,803 | 0 | 32,373 | 27.6 K to 32.4 K (+17.42 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 156.01 | 671 | 104,683 | 27,570 | 28.2 K to 27.6 K (-2.38 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,305 | 0 | 28,241 | 25.9 K to 28.2 K (+8.89 %) |
| Jul 01 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | J | 89.03 | 238 | 21,189 | 25,936 | 25.7 K to 25.9 K (+0.93 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 120.86 | 435 | 52,574 | 15,303 | 15.7 K to 15.3 K (-2.76 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 120.86 | 377 | 45,564 | 15,738 | 16.1 K to 15.7 K (-2.34 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 120.86 | 354 | 42,784 | 16,115 | 16.5 K to 16.1 K (-2.15 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 95.68 | 30,750 | 2,942,160 | 30,750 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 6,848 | 0 | 26,864 | 20 K to 26.9 K (+34.21 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 105.87 | 979 | 103,647 | 20,016 | 21 K to 20 K (-4.66 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,305 | 0 | 20,995 | 18.7 K to 21 K (+12.33 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 105.87 | 1,135 | 120,162 | 18,690 | 19.8 K to 18.7 K (-5.73 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,674 | 0 | 19,825 | 17.2 K to 19.8 K (+15.59 %) |
| Sep 03 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | P | 86.18 | 500 | 43,091 | 17,151 | 16.7 K to 17.2 K (+3.00 %) |
| Jul 02 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | J | 97.03 | 182 | 17,659 | 16,651 | 16.5 K to 16.7 K (+1.11 %) |
| Feb 13 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 117.97 | 29,298 | 3,456,285 | 29,298 | |
| Feb 13 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 6,404 | 0 | 16,469 | 10.1 K to 16.5 K (+63.63 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 111.78 | 612 | 68,409 | 10,065 | 10.7 K to 10.1 K (-5.73 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,230 | 0 | 10,677 | 8.4 K to 10.7 K (+26.40 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 111.78 | 713 | 79,699 | 8,447 | 9.2 K to 8.4 K (-7.78 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,418 | 0 | 9,160 | 6.7 K to 9.2 K (+35.86 %) |
| Aug 29 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | M | 85.79 | 11,540 | 990,017 | 6,924 | |
| Aug 29 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Sell | S | 256.69 | 18,357 | 4,712,060 | 6,742 | 25.1 K to 6.7 K (-73.14 %) |
| Aug 29 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | M | 85.79 | 11,540 | 990,017 | 25,099 | 13.6 K to 25.1 K (+85.11 %) |
| Aug 29 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | M | 85.79 | 11,540 | 990,017 | 6,924 | |
| Aug 29 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Sell | S | 256.69 | 18,357 | 4,712,060 | 6,742 | 25.1 K to 6.7 K (-73.14 %) |
| Aug 29 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | M | 85.79 | 11,540 | 990,017 | 25,099 | 13.6 K to 25.1 K (+85.11 %) |
| Aug 07 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 226.74 | 836 | 189,555 | 13,559 | 14.4 K to 13.6 K (-5.81 %) |
| Jul 03 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Buy | J | 117.84 | 180 | 21,210 | 14,395 | 14.2 K to 14.4 K (+1.27 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 159.01 | 16,050 | 2,552,111 | 16,050 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 165.87 | 550 | 91,229 | 14,215 | 14.8 K to 14.2 K (-3.73 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,004 | 0 | 14,765 | 12.8 K to 14.8 K (+15.70 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 3,074 | 0 | 12,761 | 9.7 K to 12.8 K (+31.73 %) |
| Feb 16 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 157.18 | 326 | 51,241 | 9,687 | 10 K to 9.7 K (-3.26 %) |
| Feb 16 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 157.18 | 354 | 55,642 | 10,013 | 10.4 K to 10 K (-3.41 %) |
| Dec 29 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 138.66 | 1,530 | 212,150 | 10,367 | 11.9 K to 10.4 K (-12.86 %) |
| Dec 29 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,750 | 0 | 11,897 | 8.1 K to 11.9 K (+46.03 %) |
| Nov 17 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Sell | S | 142.63 | 6,559 | 935,510 | 8,147 | 14.7 K to 8.1 K (-44.60 %) |
| Aug 08 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 122.06 | 609 | 74,335 | 14,706 | 15.3 K to 14.7 K (-3.98 %) |
| Jul 05 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Buy | J | 87.13 | 243 | 21,171 | 15,315 | 15.1 K to 15.3 K (+1.61 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Option Exercise | A | 100.38 | 15,225 | 1,528,286 | 15,225 | |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,567 | 0 | 15,072 | 11.5 K to 15.1 K (+31.00 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 100.38 | 1,051 | 105,499 | 11,505 | 12.6 K to 11.5 K (-8.37 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,450 | 0 | 12,556 | 9.1 K to 12.6 K (+37.89 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 104.28 | 391 | 40,773 | 9,106 | 9.5 K to 9.1 K (-4.12 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Payment of Exercise | F | 123.30 | 609 | 75,090 | 9,457 | 10.1 K to 9.5 K (-6.05 %) |
| Jan 03 2017 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Buy | J | 86.37 | 40 | 3,455 | 10,106 | 10.1 K to 10.1 K (+0.40 %) |
| Jul 05 2016 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Buy | J | 87.10 | 196 | 17,072 | 10,066 | 9.9 K to 10.1 K (+1.99 %) |
| Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Option Exercise | A | 85.79 | 18,464 | 1,584,027 | 18,464 | |
| Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,870 | 0 | 9,870 | 6 K to 9.9 K (+64.50 %) |
| Aug 07 2015 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Option Exercise | A | 104.59 | 25,000 | 2,614,750 | 25,000 | |
| Aug 07 2015 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
Page: 1